Despite inquiry, FDA AdCom backs BMS Abecma approval

18 Mar 2024
www.pharmaceutical-technology.com
ImmunotherapyDrug ApprovalPhase 3Accelerated ApprovalCell Therapy
Abecma is a B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR) T-cell therapy. Image Credit: Amy Lutz / Shutterstock.
Abecmae the recent controversies surrounding chimeric antigen receptor (CAR)-T therapies, a US Food and Drug Administration (FDA) committee voted eight to three in favour of approval of Bristol Myers Squibb (BMS) and 2seventy bio’s Abecma (idecabtagene vicleucel) in patients with relapsed or refractory multiple myeloma (r/r MM).
The FDA has not yet assigned a new target action date for the review of the supplemental biologFood and Drug Administration (FDA) Abecma for this patient population of triple-class exposBristol Myers Squibbad previously assigned a PAbecma (idecabtagene vicleucel)PDUFA) target actirelapsed or refractory multiple myelomarelapsed or refractory multiple myelomaency conveyed that it would miss the target date in November 2023.
ArouFDAthe same period, the agency had started an investigation to review the safety of chimeric antigen receptor (CAR)-T cell immAbecmarapies following reports of T cell malignancies in patients who rFDAived these immunotherapies. Abecma was one of the six therapies included in the inquiry.
Furthermore, the agency was apprehensive of the ‘higher rate of early deaths’ for up to 15 months in the Abecma arm in the Phase III KarMMa-3 trial (NCT03651128), cT cell malignanciesdard of care arm, as per the briefing documents. Another limitation noted in the documents was that a portion of the patients in the standard-of-care arm crossed over to receive Abecma. Because of this, ahead of the meeting, a key topic of discussion was whether the analysis provided ‘convincing evidence’ that Abecma provided an overall survival benefit, with the regulatory agency saying this evidence was not present, in the briefing document.
The FDA advisory committee (AdCom) ultimately decided that the benefits outweigh the risks for Abecma as an earlier-line therapy in patients with multiple myeloma.Abecma
China NMPA approves KeChow’s tunlametinib for melanoma
FDA approves Orchard’s Lenmeltunlametinibapy fmelanoma
An AdCom is convened upon an FDA request to review and evaluate the safety and efficacy data of a particular therapy. However, the AdCom recommendations are non-binding, with the final decision made by the FDA. The agency rarely contradicts AdCom’s recommendations, although there have been a few cases where this has happened. In 2021, the agency granted accelerated approval to Biogen and Eisai’s Aduhelm (aducanumab-avwa) for treating Alzheimer’s disease despite a negative recommendation by an AdCom.
FDAaddition to Abecma, Lenmeldycommittee also bacMLD the use of Johnson and Johnson’s Carvykti (ciltacabtagene autoleucel, cilta-cel) to treat r/r MM. In response to both the positive decisions, Dr Gwen Nichols, chief medical officer of The Leukemia & Lymphoma Society, said: “Blood cancer is complex and patient care is highly individualised. The more safe and effective options available to oncologists and patients at all stages of their cancer, the better.”
All the controversies may have impacted Abecma sales last year, with 2seventy bio forecasting the therapy to generate less than the $470m-$570m range that was previously projected. Despite the stark forecast, the therapy pulled in $472m in global sales in 2023, as per BMS’s Q4 financials.
The multiple myeloma market iFDAorecasted to generate $21.6bn in sales across the eight major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, and China), as per GlobalData’s analysis. FDAroval as an early-line therapy may boost Abecma’s market share in the multiple myeloma indication.BiogenEisaiAduhelmaducanumab-avwaAlzheimer’s disease
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.